UroGen Sees Full Year 2024 Net Product Revenues From Jelmyto To Be In The Range Of $95M-$102M
Portfolio Pulse from Benzinga Newsdesk
UroGen Pharma forecasts its full-year 2024 net product revenues from Jelmyto to be between $95 million and $102 million.
March 14, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UroGen Pharma projects its 2024 revenues from Jelmyto to be in the range of $95M-$102M, indicating strong sales performance and growth.
The projected increase in net product revenues from Jelmyto for the year 2024 suggests a positive outlook on the product's market acceptance and sales performance. This forecast is likely to be viewed positively by investors, potentially leading to an increase in UroGen Pharma's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100